 Brickell Biotech Inc NASDAQ: BBI agreed to sell sofpironium bromide rights to Australia-based Botanix Pharmaceuticals Limited. Brickell will receive upfront and potential near-term regulatory milestone payments over the next 18 months of up to 9 million. 